2019 International Congress Archives - Page 130 of 217

Objective assessment of motor states in Parkinson’s disease using partial least squares and smartphone data

M. Memedi, S. Aghanavesi (Borlänge, Sweden)
Objective evaluation criteria for diagnosis of spasmodic dysphonia

K. Kleim, K. Simonyan, T. Ball (Freiburg, Germany)
Objective quantifiable assessment of nocturnal movements in patients with Parkinson’s disease using a wearable sensor

A. Mirelman, I. Hillel, L. Rochester, A. Nieuwboer, B. Bloem, L. Avanzino, S. Shema-Shiratzki, I. Maidan, T. Herman, J. Cederbaum, N. Giladi, J. Hausdorff (Tel Aviv, Israel)
Occurrence of brain capillary dysfunction in patients with REM sleep behavior disorder

S. Eskildsen, A. Iranzo, M. Stokholm, K. Stær, K. østergaard, M. Eroles, M. Otto, K. Svendsen, A. Pla, D. Vilas, P. Borghammer, J. Santamaria, A. Møller, C. Gaig, D. Brooks, E. Tolosa, L. østergaard, N. Pavese (Aarhus N, Denmark)
Ocular Motor Dysfunction as the Predictable Milestone of Life Prognosis in Progressive Supranuclear Palsy

T. Ishihara, T. Oeda, S. Tomita, A. Umemura, M. Kohsaka, K. Park, M. Tahara, K. Yamamoto, H. Sawada (Kyoto, Japan)
Ocular Motor Findings in Spinocerebellar Ataxia Type 17

SU. Lee, JY. Choi, JM. Kim, JS. Kim (Seoul, Republic of Korea)
Oculopalatal tremor (OPT) in a patient with anti-GAD brainstem encephalitis: A case report

MF. Ip, SH. Li, TY. Wai, LY. Wong (Sheung Shui, Hong Kong)
Olfactory dysfunction in Parkinson’s disease

N. Jalami, H. Bentahar, M. Chraa, N. Kissani (Marrakech, Morocco)
Olfactory Hallucinations as a Non-motor sign of Parkinson’s disease- a cross sectional study

S. Chandra, M. Schiess, R. Mehanna (Houston, TX, USA)
Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease

G. Hatipoglu, S. Ozkaynak (Antalya, Turkey)
Oligomeric Alpha-synuclein in Erythrocyte Membrane in Early Parkinson’s Disease

GL. Liu, C. Tian, T. Feng (Beijing, China)
OnabotulinumtoxinA Reduces Disability in Treatment-Naive Adult Patients with Spasticity: Results from the ASPIRE Study

W. Jost, A. Ellenbogen, G. Wittenberg, K. Ngo, J. Largent, A. Zuzek, G. Francisco, A. Esquenazi (Irvine, CA, USA)
OnabotulinumtoxinA treatment in adults with spasticity reduces caregiver burden: Results from the ASPIRE study

A. Esquenazi, A. Ellenbogen, G. Wittenberg, K. Ngo, J. Largent, A. Zuzek, G. Francisco, W. Jost (Elkins Park, PA, USA)
One-year follow-up of subthalamic deep brain stimulation in Parkinson’s disease

L. Barcelos, M. Tosin, M. Marinho, C. Silva, R. Saba, S. Silva, V. Borges, H. Ferraz (Sao Paulo, Brazil)
Online determination of the STN “sweet spot” based on beta-power measured with directional macro-contacts of the final DBS lead

M. Scherer, L. Milosevic, R. Guggenberger, A. Malekmohammadi, G. Naros, D. Weiss, A. Gharabaghi (Tübingen, Germany)
Onset of action for rimabotulinumtoxinB in the treatment of adult sialorrhea

L. Bahroo, S. Isaacson, R. Pahwa, D. Chary, T. Clinch, M. Lew (Washington, DC, USA)
Onset symptoms and time to diagnosis in Friedreich´s Ataxia

E. Indelicato, W. Nachbauer, A. Eigentler, M. Amprosi, P. Giunti, C. Mariotti, J. Arpa, A. Dürr, T. Klopstock, L. Schöls, T. Klockgether, K. Bürk, M. Pandolfo, J. Schulz, S. Boesch (Innsbruck, Austria)
Open-label safety and tolerability of L-Dihydroxyphenylserine (L-DOPS) and high dose carbidopa therapy in Parkinson’s disease patients

K. Hay, K. Mcdonell, P. Trujillo, M. Donahue, N. van Wouwe, D. Claassen (Nashville, TN, USA)
Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression

J. Norton, D. Fredericks, G. Alva, J. Aldred, B. Coate, D. Dekarske, M. Cantillon, R. Owen (San Deigo, CA, USA)
Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations

C. Liguori, M. Pierantozzi, R. Cerroni, NB. Mercuri, A. Stefani (Rome, Italy)
Opicapone and levodopa-carbidopa intestinal gel infusion: a cost saving analysis in the United Kingdom

V. Leta, D. van Wamelen, A. Sauerbier, S. Jones, A. Podlewska, D. Trivedi, M. Parry, P. Odin, A. Storch, Z. Pirtošek, A. Antonini, K. Ray Chaudhuri (London, United Kingdom)
Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials

R. Hauser, O. Rascol, W. Poewe, J. Ferreira, A. Lees, O. Klepitskaya, G. Liang, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Tampa, FL, USA)
Opicapone improves motor and non-motor wearing off symptoms in Parkinson’s disease: an observational real-world study

C. Oehlwein, K. Mittmann, D. Sarkisjan, J. Baron, M. Oehlwein, K. Witt (Gera, Germany)
Opicapone odds ratio in relative OFF-time reduction: a post-hoc analysis from combined BIPARK-I and II data

J. Rocha, W. Poewe, O. Rascol, A. Lees, J. Ferreira, A. Santos, D. Magalhães, P. Soares-da-Silva (Coronado, Portugal)
OPICAPONE: REAL WORLD EVIDENCE IN TOLEDO´S MOVEMENT DISORDERS UNIT

JC. Segundo-Rodríguez, N. López-Ariztegui, MI. Morales-Casado, N. García-Alvarado, A. Avila-Fernández, J. Pérez-Matos (Toledo, Spain)
Opinions and clinical practices related to diagnosing and managing patients with functional (psychogenic) movement disorders: from 2009 to 2019

K. Lafaver, D. Bega, M. Hallett, A. Lang, S. Lidstone, C. Maurer, F. Morgante, D. Perez, C. Stephen, J. Stone, T. Teodoro, A. Wu, A. Dwivedi, A. Espay (Louisville, KY, USA)
Opposing effects of levodopa on basal ganglia activity in Parkinson’s disease during motion and rest

R. Jech, S. Holiga, F. Růžička, H. Möller, J. Roth, M. Schroeter, E. Růžička, K. Mueller (Prague, Czech Republic)
Opsoclonus and ataxia in the setting of synchronous primary malignancies

H. Leal Bailey, S. Wijemanne Sarathkumara, R. Knightstep (San Antonio, TX, USA)
Opsoclonus-Myoclonus-Ataxia Syndrome – Ljubljana University Children’s Hospital clinical series

J. Orazem Mrak, D. Osredkar, D. Neubauer (Ljubljana, Slovenia)
Opsoclonus-myoclonus-ataxia syndrome associated to rubella

BED. Ines, BRA. Zeineb, HAM. Salma, ZAO. Jamel, MRI. Ridha (Tunis, Tunisia)
Optimal Parameters of Deep Brain Stimulation in Essential Tremor: A Meta-Analysis and Novel Programming Strategy

D. Bogdan, T. van Laar, M. Oterdoom, G. Drost, M. van Dijk, M. Beudel (Groningen, Netherlands)
Optimal treatment of geniospasm: a case report and review of the literature

M. Hull, M. Parnes (Houston, TX, USA)
Oromandibular Dystonia as an Initial Manifestation of Parkinson’s Disease: 2 Case Reports

F. Gao (San Francisco, CA, USA)
Oromandibular Dystonia: Clinical Data from 68 Patients

M. Balal, M. Demirkiran (Adana, Turkey)
Orthostatic jaw tremor, a diagnostic challenge

R. Moraes, F. Sousa, P. Pereira, J. Freitas, L. Santos, J. Junior, M. Rocha (Sao Paulo, Brazil)
Orthostatic tremor – a case series

L. Colmenares, L. Jones, Y. Tai, P. Bain (London, United Kingdom)
Orthostatic Tremor Mimics: A Case Series

M. Minar, I. Straka, Z. Kosutzka (Bratislava, Slovakia)
Oscillaotory activity in the globus pallidus internus in patients with Parkinson’s disease

P. Zhuang, M. Hallett, D. Meng, Y. Zhang, J. Li, J. Li (Beijing, China)
Osteopathic Manipulative Medicine to Improve Balance and Quality of Life in Parkinson Disease

S. Yao, J. Docherty, J. Mancini, A. Leder, J. Difrancisco-Donoghue (Old Westbury, NY, USA)
Outcomes After Weighted Lumbosacral Orthosis (LSO) and Exercises in Patients with Progressive Cerebellar Ataxia

S. Mele (Philadelphia, PA, USA)
Outcomes of a Prospective, Multicenter, International Registry of Deep Brain Stimulation for Parkinson’s Disease

J. Vesper, R. Jain, A. Wang, H. Scholtes, V. Study Group, G. Deuschl (Düsseldorf, Germany)
Outcomes of Percutaneous Endoscopic Gastrostomy (PEG) Feeding in Parkinson’s

L. Brown, M. Oswal, H. Martin, A. Lindahl, R. Skelly (Derby, United Kingdom)
Outcomes of the first-in-human study with a recombinant botulinum toxin E (rBoNT-E): safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA

L. Pons, C. Vilain, P. Picaut (Cambridge, MA, USA)
Overnight unilateral withdrawal of VIM-DBS to identify reversibility of gait disturbances

D. Kroneberg, D. Kübler, B. Al-Fatly, AC. Meyer, GH. Schneider, A. Kühn (Berlin, Germany)